HealthyPhase 1NCT06662773
Drug-Drug Interaction (DDI) Study for TQB3616
A Phase 1 study testing TQB3616 capsule + itraconazole and TQB3616 capsule + rifampicin in people with Healthy, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. at 1 site in China.
Trial summary
To evaluate the effect of itraconazole/rifampicin on the pharmacokinetics of TQB3616 capsules. To assess the safety of a single dose of oral TQB3616 capsules and in combination with itraconazole/rifampicin. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- TQB3616 capsule + itraconazole and TQB3616 capsule + rifampicin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteChina
- Study dates
- Nov 2024to Jul 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- At the time of signing the informed consent form, the age is 18~45 years old (including the cut-off value), both male and female;
- Females ≥ 45kg, males ≥ 50kg, body mass index (BMI) is 19~26 kg/m^2 (including the critical value), BMI = weight (kg)/height^2 (m^2);
- Those with normal vital signs, physical examination, clinical laboratory examination, imaging examination, 12-lead electrocardiogram, or abnormal but no clinical significance as judged by the investigator;
- Subject is able to comply with study procedures, voluntarily participate in this trial, and sign an informed consent form in writing.
Who cannot join
- Those who have suffered or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic abnormalities or any other diseases that can interfere with the test results;
- Those who have systemic/local acute infection before taking the study drug;
- Those with a history of food or drug allergies, or allergies;
- Those who have dysphagia or suffer from any gastrointestinal diseases that affect drug absorption at the time of screening;
- Those who cannot accept intravenous indwelling needle puncture blood vessels to collect blood samples, or the subjects cannot tolerate venipuncture, or have a history of needle fainting or blood sickness;
- Regular drinkers within 6 months before the first dose, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine) or those who have a positive alcohol breath test at screening;
Show all 18Show fewer
- History of major surgical operation (defined as difficult and complex intraoperative surgery, such as gastric and duodenal surgery, partial nephrectomy, radical resection of malignant tumor, etc.) within 3 months before the first dose, or have taken investigational drugs or participated in other drug clinical trials;
- Blood donation or massive blood loss (>400 mL) within 3 months before the first dose;
- Those who have used drugs within 3 months before the first dose, or those who have a positive drug screen, or those who have a history of drug abuse within five years before screening;
- Those who smoke more than 5 cigarettes per day within 3 months before the first dose or those who cannot stop using any tobacco products during the trial;
- Daily consumption of excessive tea, coffee, and/or caffeinated beverages (more than 8 cups, 1 cup=250 mL) within 30 days prior to the first dose;
- Use of any drug that inhibits or induces the hepatic metabolism of the drug within 30 days before the first dose (such as: CYP3A4 inducers carbamazepine, dexamethasone, rifampicin, phenytoin, phenobarbital, St. John's worn, etc.); CYP3A4 inhibitors itraconazole, ketoconazole, clarithromycin, telithromycin, lopinavir, ritonavir, etc.);
- Have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before the first dose;
- Those who have taken a special diet (such as grapefruit) or other factors that affect the absorption, distribution, metabolism, and excretion of drugs within 7 days before the first dose;
- Ingestion of chocolate, any caffeine-containing, or xanthine-rich food or drink 48 hours prior to the first dose;
- Those who have special dietary requirements and cannot comply with the unified diet;
- Pregnant or lactating women, as well as subjects and their spouses who have childbearing, or sperm donation, or egg donation plans within 3 months from signing the informed consent form to the last dose, or who cannot guarantee the use of effective contraception during this period (taking one or more non-drug contraceptive measures during the trial);
- Subjects who are judged by the investigator to be unsuitable to participate.
Trial locations and contacts
1 site in 1 country.
China1 site
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, 100730
Laichun Lu, Doctor, 138 8393 3701, lulaicq@163.com
About this study
Official title: Phase I Clinical Trial Evaluating Drug Drug Interactions of TQB3616 Capsules
To evaluate the effect of itraconazole/rifampicin on the pharmacokinetics of TQB3616 capsules.
To assess the safety of a single dose of oral TQB3616 capsules and in combination with itraconazole/rifampicin.
- Conditions
- Healthy
- Being tested
- TQB3616 capsule + itraconazole, TQB3616 capsule + rifampicin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TQB3616 capsule + itraconazoleDrug
C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors
TQB3616 capsule + rifampicinDrug
C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer
| Study group | Role | What they receive |
|---|---|---|
| Inhibitor group | Experimental | Oral TQB3616 capsules 60 mg after a single meal on days 1 and 13; On days 10 to 21, itraconazole capsules 200mg were taken orally once a day for 12 days after meals. Receives: Drug: TQB3616 capsule + itraconazole |
| Inducer group | Experimental | 180mg of TQB3616 capsules orally after a single meal on days 1 and 17; Oral administration of rifampicin capsules 600mg from day 10 to day 25 on the peritoneum once a day for 16 consecutive days, of which rifampicin capsules 600mg and TQB3616 capsules 180mg were taken at the same time after meals on the 17th day. Receives: Drug: TQB3616 capsule + rifampicin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peak concentration (Cmax)
Maximum plasma drug concentration
Measured: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
Area under drug time curve (AUC0-t)
Area under the plasma concentration time curve from time 0 to last time of quantifiable concentration.
Measured: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
Area under drug time curve (AUC0-∞)
Area under the plasma concentration-time curve from time 0 extrapolated to infinite time.
Measured: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
Secondary outcomes (1)
Adverse event rate
Incidence and severity of adverse events and serious adverse events, and abnormal laboratory examination indicators.
Measured: From before the first administration to 26 days after the administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2024
- Study startNov 2024 (estimated)
- Primary completionMar 2025 (estimated)
- Study completionJul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06662773
- Sponsor's protocol ID
- TQB3616-I-05
- Status last verified
- Aug 2024
- First submitted
- 28 Oct 2024
- Last updated
- 29 Oct 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I Clinical Trial Evaluating Drug Drug Interactions of TQB3616 Capsules
- ClinicalTrials.gov ID
- NCT06662773
- Acronym / sponsor ID
- TQB3616-I-05
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- Nov 2024 (estimated)
- Primary completion
- Mar 2025 (estimated)
- Study completion
- Jul 2025 (estimated)
- First posted
- 29 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the effect of itraconazole/rifampicin on the pharmacokinetics of TQB3616 capsules.
To assess the safety of a single dose of oral TQB3616 capsules and in combination with itraconazole/rifampicin.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Inhibitor group | Experimental | Drug: TQB3616 capsule + itraconazoleOral TQB3616 capsules 60 mg after a single meal on days 1 and 13; On days 10 to 21, itraconazole capsules 200mg were taken orally once a day for 12 days after meals. |
| Inducer group | Experimental | Drug: TQB3616 capsule + rifampicin180mg of TQB3616 capsules orally after a single meal on days 1 and 17; Oral administration of rifampicin capsules 600mg from day 10 to day 25 on the peritoneum once a day for 16 consecutive days, of which rifampicin capsules 600mg and TQB3616 capsules 180mg were taken at the same time after meals on the 17th day. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- At the time of signing the informed consent form, the age is 18~45 years old (including the cut-off value), both male and female;
- Females ≥ 45kg, males ≥ 50kg, body mass index (BMI) is 19~26 kg/m^2 (including the critical value), BMI = weight (kg)/height^2 (m^2);
- Those with normal vital signs, physical examination, clinical laboratory examination, imaging examination, 12-lead electrocardiogram, or abnormal but no clinical significance as judged by the investigator;
- Subject is able to comply with study procedures, voluntarily participate in this trial, and sign an informed consent form in writing.
Key exclusion criteria (18 listed)
- Those who have suffered or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic abnormalities or any other diseases that can interfere with the test results;
- Those who have systemic/local acute infection before taking the study drug;
- Those with a history of food or drug allergies, or allergies;
- Those who have dysphagia or suffer from any gastrointestinal diseases that affect drug absorption at the time of screening;
- Those who cannot accept intravenous indwelling needle puncture blood vessels to collect blood samples, or the subjects cannot tolerate venipuncture, or have a history of needle fainting or blood sickness;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TQB3616 capsule + itraconazoleC2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors | Drug | Inhibitor group |
| TQB3616 capsule + rifampicinC2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer | Drug | Inducer group |
Primary outcome
Peak concentration (Cmax)
Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
Maximum plasma drug concentration
Area under drug time curve (AUC0-t)
Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
Area under the plasma concentration time curve from time 0 to last time of quantifiable concentration.
Area under drug time curve (AUC0-∞)
Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
Area under the plasma concentration-time curve from time 0 extrapolated to infinite time.
1 secondary outcome
Adverse event rate
Time frame: From before the first administration to 26 days after the administration
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2024.
Related trials for Healthy
RecruitingObservational study
Studies of Blood Flow to the Brain During Thought
Healthy Volunteer
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
Enrolling by invitationObservational study
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Neoplasms, Hematologic Neoplasms
Enrolling by invitationObservational study
Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick
Healthy Donors
RecruitingObservational study
Collection and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers
Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing TQB3616 capsule + itraconazole and TQB3616 capsule + rifampicin in people with Healthy, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Laichun Lu (138 8393 3701, lulaicq@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peak concentration (Cmax) (time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2024; AzTrials last refreshed its copy on 6 Nov 2026.